5-fluoro-uracil (5-FU) cardiotoxicity has been often reported during c
hemotherapy. We collect four atypical cases of cardiac side effects in
patients treated by 5-FU for head and neck tumors. We review the lite
rature about the subject, and we propose criteria to detect patients w
ith a high risk level, and to prevent this adverse effect incidence.